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Abstract
Objective: To examine the ability of three different proteinuria 
assessment methods (urinary dipstick, spot urine 
protein:creatinine ratio [Pr/Cr], and 24-hour urine collection) to 
predict adverse pregnancy outcomes
Methods: We performed a prospective multicentre cohort study, PIERS 
(Preeclampsia Integrated Estimate of RiSk), in seven academic 
tertiary maternity centres practising expectant management of 
preeclampsia remote from term in Canada, New Zealand, and 
Australia Eligible women were those admitted with preeclampsia 
who had at least one antenatal proteinuria assessment by urinary 
dipstick, spot urine Pr/Cr ratio, and/or 24-hour urine collection
Proteinuria assessment was done either visually at the bedside (by 
dipstick) or by hospital clinical laboratories for spot urine  
Pr/Cr and 24-hour urine collection We calculated receiver 
operating characteristic area under the curve (95% CI) for each 
proteinuria method and each of the combined adverse maternal 
outcomes (within 48 hours) or adverse perinatal outcomes  
(at any time) Models with AUC ≥ 070 were considered of interest
Analyses were run for all women who had each type of proteinuria 
assessment and for a cohort of women (“ALL measures”) who had 
all three proteinuria assessments
Results: More women were proteinuric by urinary dipstick 
(≥ 2+, 614%) than by spot urine Pr/Cr (≥ 30g/mol, 504%) or 
24-hour urine collection (≥ 03g/d, 347%) Each proteinuria 
measure evaluated had some discriminative power, and dipstick 
proteinuria (categorical) performed as well as other methods No 
single method was predictive of adverse perinatal outcome
Conclusion: The measured amount of proteinuria should not be used 
in isolation for decision-making in women with preeclampsia
Dipstick proteinuria performs as well as other methods of 
assessing proteinuria for prediction of adverse events
Résumé
Objectif : Examiner la capacité de trois méthodes d’évaluation 
différentes de la protéinurie (test d’urine par bandelette réactive, 
rapport protéine:créatinine [Pr/Cr] d’échantillon d’urine ponctuel 
et collecte d’urine sur 24 heures) de prédire les issues de 
grossesse indésirables
Méthodes : Nous avons mené une étude de cohorte multicentrique 
prospective (PIERS ou Preeclampsia Integrated Estimate of 
RiSk) dans sept centres de maternité tertiaires universitaires 
pratiquant la prise en charge non interventionniste de la 
prééclampsie ne se manifestant pas à terme au Canada, en 
Nouvelle-Zélande et en Australie Les femmes admissibles 
étaient celles qui étaient hospitalisées en raison d’une 
prééclampsie et qui avaient subi au moins une évaluation 
prénatale de la protéinurie au moyen d’un test d’urine par 
bandelette réactive, du rapport Pr/Cr d’échantillon d’urine 
ponctuel et/ou de la collecte d’urine sur 24 heures L’évaluation 
de la protéinurie a été effectuée de façon visuelle au chevet 
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de la patiente (au moyen d’une bandelette réactive) ou par 
l’intermédiaire des laboratoires cliniques hospitaliers pour ce 
qui est du rapport Pr/Cr d’échantillon d’urine ponctuel et de la 
collecte d’urine sur 24 heures Nous avons calculé la surface 
sous la courbe d’ef¿cacité du récepteur (IC à 95 %) pour 
chacune des méthodes d’évaluation de la protéinurie et chacune 
des issues maternelles indésirables combinées (dans un délai 
de 48 heures) ou chacune des issues périnatales indésirables 
(à quelque moment que ce soit) Les modèles dont la surface 
sous la courbe étaient ≥ 0,70 ont été considérés dignes d’intérêt
Les analyses ont été menées pour toutes les femmes qui ont 
subi chacun des types d’évaluation de la protéinurie et pour une 
cohorte de femmes (« TOUTES les mesures ») ayant subi les 
trois types d’évaluation de la protéinurie
Résultats : Plus de femmes se sont avérées être protéinuriques au 
moyen d’un test d’urine par bandelette réactive (≥ 2+, 61,4 %) 
qu’au moyen du rapport Pr/Cr d’échantillon d’urine ponctuel 
(≥ 30 g/mol, 50,4 %) ou de la collecte d’urine sur 24 heures 
(≥ 0,3 g/d, 34,7 %) Chacune des mesures de la protéinurie 
évaluée comptait un certain pouvoir discriminateur; de plus, 
l’évaluation de la protéinurie au moyen d’un test d’urine par 
bandelette réactive (catégorique) a obtenu un rendement 
équivalant à celui des autres méthodes Aucune méthode unique 
n’a permis de prédire les issues périnatales indésirables
Conclusion : La quantité mesurée de protéinurie ne devrait pas être 
utilisée de façon isolée aux ¿ns de la prise de décision chez les 
femmes qui présentent une prééclampsie L’évaluation de la 
protéinurie au moyen d’un test d’urine par bandelette réactive 
offre un rendement équivalant à celui des autres méthodes pour 
ce qui est de la prédiction des événements indésirables
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INTRODUCTION
Maternal and perinatal complications cluster with the diagnosis of  preeclampsia, usually deÀned as 
gestational hypertension with proteinuria, and place the 
assessment of  urinary protein excretion as a core element 
of  antenatal care. As the amount of  protein excretion 
in women with preeclampsia may reÁect maternal and 
perinatal risk, various deÀnitions of  heavy proteinuria have 
been incorporated into deÀnitions of  severe preeclampsia 
and suggested as a speciÀc indication for delivery.1,2
Options for quantifying proteinuria include dipstick 
testing, spot urinary protein to creatinine ratio, and various 
timed urine collections for estimation of  protein excretion, 
the most common being the 24-hour collection. There 
are insufÀcient data to deÀne an abnormal albumin to 
creatinine ratio in pregnancy3,4 and there is no information 
about its prognostic signiÀcance related to adverse 
pregnancy outcomes.
While accepted as the gold standard for assessing 
proteinuria, the 24-hour urine collection is often affected 
by inaccurate collecting.5 Also, it is unclear whether there 
is a level of  protein excretion that usefully deÀnes patients 
as being at increased risk of  adverse outcomes.6 From a 
number of  small, heterogeneous studies, heavy proteinuria 
(5 g/d, 10 g/d, or an increase by 2 g/d) may be somewhat 
useful or useful as test for predicting eclampsia, stillbirth, 
perinatal death, SGA infants, or NICU admission.7–15
Within a cohort of  women admitted to hospital with 
preeclampsia, we examined whether the amount of  
antenatal proteinuria assessed by urinary dipstick, spot 
urinary Pr/Cr, or 24-hour urine collection is predictive of  
adverse maternal or perinatal outcomes.
METHODS
PIERS is a multicentre study of  women with preeclampsia 
admitted to academic tertiary obstetric care centres in 
which there is a general policy of  expectant management 
of  preeclampsia remote from term in Canada (British 
Columbia’s Women’s Hospital/University of  British 
Columbia, Vancouver, BC; Kingston General Hospital/
Queen’s University, Kingston, ON; The Ottawa Hospital 
[General Campus]/University of  Ottawa, Ottawa, ON; 
and Centre Hospitalier universitaire de Sherbrooke/
Université de Sherbrooke, QC), the United Kingdom (St. 
James Hospital/University of  Leeds, Leeds, Yorkshire), 
New Zealand (Christchurch Women’s Hospital/University 
of  Otago, Christchurch), and Australia (King Edward 
Memorial Hospital for Women/University of  Western 
Australia, Subiaco, Western Australia).
PIERS was conducted as a continuous quality improvement 
project in three sites using predetermined guidelines 
for the initial assessment and ongoing surveillance of  
women admitted to hospital with suspected or conÀrmed 
preeclampsia.16–18 In four sites, women were required to give 
informed consent. Women were included in the study if  they 
were admitted to hospital with preeclampsia, or developed 
preeclampsia following admission, and had one or more 
measures of  proteinuria before delivery. Women were 
excluded if  they were admitted to hospital in spontaneous 
labour or had achieved any component of  the maternal 
outcome prior to fulÀlling either the eligibility criteria or the 
collection of  the potential predictors we chose to evaluate.
ABBREVIATIONS
AUC area under the curve
BP blood pressure
HELLP hemolysis, elevated liver enzymes, low platelet count
PIERS Preeclampsia Integrated Estimate of RiSk
Pr/Cr protein:creatinine ratio
ROC receiver operating characteristic
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Preeclampsia was deÀned as (1) blood pressure 
≥ 140/90 mmHg (at least one component twice, ≥ 4 hours 
apart, after 20 weeks’ gestation) and either proteinuria 
(≥ 2+ by dipstick, ≥0.3 g/d by 24-hour urine collection, 
or ≥ 30 mg/mmol by spot urine Pr/Cr) or hyperuricemia 
(greater than local upper limit of  normal for non-pregnant 
individuals), (2) HELLP syndrome even in the absence 
of  hypertension or proteinuria,19 or (3) superimposed 
preeclampsia, deÀned as pre-existing hypertension with 
new proteinuria, new hyperuricemia, and/or accelerated 
hypertension (diagnosed by the clinician and deÀned as 
either rapidly increasing requirements for antihypertensives, 
a systolic BP > 170 mmHg, or a diastolic BP > 120 mmHg). 
This inclusive deÀnition was chosen to reÁect both 
the variable and multisystem nature of  preeclampsia at 
presentation and the spectrum of  women seen in clinical 
practice.20,21
The components of  the combined adverse maternal 
outcome were developed by Delphi consensus (members 
of  consensus listed in the Appendix),22,23 as follows:
11. maternal mortality, or one or more of  hepatic 
dysfunction, hematoma, or rupture
12. eclampsia, Glasgow coma score < 13
13. stroke
14. reversible ischemic neurological deÀcit
15. transient ischemic attack
16. posterior reversible encephalopathy
17. cortical blindness or retinal detachment
18. need for positive inotrope support
19. infusion of  a third parenteral antihypertensive
10. myocardial ischemia/infarction (symptoms, ECG 
changes [ST segment changes, Q waves], biochemical 
markers [troponin, CK-MB]), coronary artery inter-
vention, or pathological Àndings
11. acute renal insufÀciency (serum creatinine  
>150 mM/L [women without pre-existing renal disease] 
or > 200 mM/L [with pre-existing renal disease]), dialysis, 
pulmonary edema, requirement ≥ 50% FiO2 for ≥ 1 hour
12. intubation (other than for Caesarean section)
13. transfusion of  any blood product.
The adverse perinatal outcome was deÀned as perinatal 
or infant mortality, admission to NICU for greater than 
48 hours, or both.
Outcomes were assessed Àrst at 48 hours after eligibility, 
as that is the time frame for corticosteroid administration 
remote from term and decisions about the place of  
delivery, in utero transfer from level one and two units, and 
labour induction. Epochs of  seven days and “any time” 
were also evaluated. The worst value (e.g., highest dipstick 
proteinuria) prior to outcome occurrence or completion of  
the relevant epoch was used in the analysis.
Assessment of  proteinuria was among the possible 
maternal and fetal predictors of  adverse outcomes.24,25 
Methods considered were urinary dipstick testing (from 
negative to 4+), spot urine Pr/Cr (mg/mmol), and 24-hour 
urinary protein (g/d). Dipstick proteinuria was assessed 
using bedside visual interpretation, and results of  testing 
analyzed as both a continuous and categorical variable 
to determine which analytical approach would be more 
informative. For laboratory measurement of  proteinuria, 
pyrogallol red (n = 6 centres) or benzathonium chloride 
(n = 1 centre) were used in routine hospital laboratories 
as part of  clinical care. All results were freely available to 
clinicians. Proteinuria results were assessed as continuous 
variables without designation of  an arbitrary cut-off.
Proteinuria measurements were collected antenatally and 
within 48 hours of  eligibility, and the most abnormal values 
in any 24-hour period were recorded. If  absent, the last 
observation carried forward method was used such that any 
observation performed within 14 days before admission 
was used. This approach underestimates the effect of  a 
variable in modelling.26 Also, clinicians do not re-evaluate 
what they believe has not changed. Missing values and 
misclassiÀcation were addressed by abstractor training, 
development and validation of  the PIERS Access database, 
feasibility and development studies using that database, and 
random re-abstraction of  charts. MisclassiÀcation errors 
were minimized by database surveillance and reabstraction, 
which occurred randomly in 5% of  cases and for all cases 
of  adverse maternal or perinatal outcomes, suspected 
or conÀrmed. The study was pragmatic and therefore 
consistent with clinical care. Test reproducibility was not 
examined. We relied on local laboratory quality control 
procedures for ensuring test reproducibility.
Customized case report forms and a Microsoft Access 
database were created for data entry and utilized by all 
participating sites. Data were collected from patient medical 
records.
Univariable logistic regression was used to evaluate 
the relationship between each measure of  proteinuria 
(i.e., dipstick, spot Pr/Cr, and 24-hour) and each of  the 
following: the adverse maternal outcome (over the Àrst 48 
hours, 7 days, and at any time) and the adverse perinatal 
outcome (at any time). The analyses were performed for 
women who had one of  the three measures of  proteinuria 
and for women who had all three measures of  proteinuria. 
Beta-coefÀcients were exponentiated to obtain odds ratios, 
which reÁected the change in the odds of  the outcome 
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occurring for every unit change in the independent variable 
(i.e., proteinuria assessment in this study). For each analysis, 
area under the curve of  the receiver operating characteristic 
was computed in which, over a range of  possible cut-
points that could deÀne a positive test, the relation between 
the true-positive and false-positive ratios was shown. An 
AUC ROC of  > 0.7 is considered the minimum to indicate 
an adequately discriminative test; 1.0 indicates perfect 
discrimination and 0.5 is non-discriminative (i.e., no better 
than Áipping a coin). For an adequately discriminative test, 
sensitivity, speciÀcity, false-positive probability, and false-
negative probability were calculated based on different 
cut-points. Statistical analyses were performed using 
the statistical software R (R Foundation for Statistical 
Computing, Vienna, Austria).
A sensitivity analysis was performed excluding women 
diagnosed on the basis of  hyperuricemic hypertension 
rather than proteinuric hypertension.
Research ethics board approval for the study was obtained 
at all participating sites.
RESULTS
Between September 1, 2003, and January 31, 2010, data 
from 2023 women were entered into the PIERS database 
from seven international sites. Antenatal assessment of  
proteinuria by one or more methods was documented 
for 2002 women, of  whom 434 women had proteinuria 
assessment by urinary dipstick, spot urine Pr/Cr, and 24-
hour urine collection (i.e., the ALL measures cohort). The 
amount of  proteinuria (median and interquartile range) did 
not vary between centres for each method of  proteinuria 
assessment (data not shown).
Demographic characteristics for the ALL measures cohort 
(n = 434) and the cohorts for each of  the three methods 
of  proteinuria assessment are shown in Table 1. For 
completeness, data on the full PIERS cohort with any 
antenatal assessment of  proteinuria (n = 2002) are included 
in Table 1. Women in the ALL measures cohort and 24-hour 
urinary protein cohort were enrolled earlier in pregnancy. 
Compared with the other groups, women in the 24-hour 
Table 1. Baseline characteristics of women with antenatal preeclampsia in PIERS cohort
Full cohort
N = 2002
Women with 
ALL measures of 
proteinuria
N = 434
Dipstick 
proteinuria 
cohort
N = 1949
Spot urine  
Pr/Cr cohort
N = 1411
24-hour urinary 
protein cohort
N = 676 P*
Median (IQR)
Maternal age, years 31 (27–36) 33 (28–36) 31 (27–36) 31 (27–36) 32 (27–36) 0154
GA at eligibility–weeks 360 (329–383) 342 (311–364) 360 (329–383) 360 (330–381) 339 (306–363) < 0001
n (%)
GA < 34 weeks at eligibility 633 (316) 203 (468) 615 (316) 438 (310) 341 (504) < 0001
Multiple pregnancy 192 (96) 54 (124) 183 (94) 130 (92) 79 (117) 0079
Parity ≥ 1 573 (286) 140 (322) 558 (286) 416 (294) 204 (302) 0485
Description of preeclampsia
Hypertension and proteinuria 1330 (664) 295 (679) 1297 (665) 946 (670) 456 (675)
0047
Hypertension and hyperuricemia 317 (158) 33 (76) 310 (159) 215 (152) 64 (95)
HELLP without hypertension or 
proteinuria
52 (26) 13 (30) 51 (26) 39 (28) 19 (28)
Superimposed preeclampsia 303 (151) 93 (214) 291 (149) 211 (150) 137 (203)
Peak blood pressure† (mmHg) Median (IQR)
Mean arterial pressure 120 (114–130) 120 (113–128) 121 (114–129) 120 (113–128) 121 (115–130) 0004
Systolic BP 160 (150–176) 160 (150–174) 160 (150–176) 160 (150–175) 162 (150–178) 0007
Diastolic BP 102 (9725–110) 1005 (96–110) 102 (98–110) 100 (96–110) 102 (99–110) 0008
n (%)
On anti-hypertensive treatment 1369 (684) 337 (776) 1327 (681) 977 (692) 527 (78) < 0001
Smoking (any) during pregnancy 246 (123) 52 (120) 236 (121) 180 (128) 82 (121) 0887
GA: gestational age; IQR (interquartile range)
* Continuous variables were compared by ANOVA or Kruskal-Wallis, and categorical variables by chi-square
† Not mutually exclusive
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urinary protein cohort more often had superimposed 
preeclampsia and higher BP, although the absolute increase 
was small. Women in the dipstick cohort more frequently had 
preeclampsia based on the deÀnition requiring hypertension 
and hyperuricemia. Otherwise, the groups were similar, 
including use of  antihypertensive therapy and smoking.
Data on the results of  proteinuria testing are shown in Table 
2. The degree of  proteinuria as assessed by Pr/Cr or 24-
hour urinalysis did not differ between groups. The degree 
of  proteinuria as assessed by dipstick proteinuria did differ 
between groups, although the difference was not felt to be 
clinically signiÀcant (e.g., between 37% and 43% of  women 
in each group had dipstick proteinuria of  3 or 4+). Twenty-
two percent of  women had nephrotic-range proteinuria 
(i.e., ≥ 3 g/d) and < 6% had a serum albumin < 20 g/L. All 
measures were done in the context of  clinical care without 
reported adverse effects of  the tests themselves.
The incidence of  the combined adverse maternal outcome 
within 48 hours of  eligibility (Table 3) did not differ between 
the cohorts, but the occurrence of  combined adverse 
perinatal outcome was signiÀcantly different between 
the cohorts (Table 4). The combined perinatal outcome 
occurred least frequently in the dipstick cohort (4%) and 
most frequently in the 24-hour urinary protein cohort 
(10.2%). Women in the ALL measures and 24-hour urinary 
protein cohorts delivered earlier, had greater prolongation 
of  pregnancy (days from admission to delivery), and lower 
birth weights than the dipstick proteinuria or spot urine 
Pr/Cr cohorts.
In univariable analysis, all measures of  proteinuria had a 
weak discriminative ability to distinguish between women 
with and without an adverse maternal outcome within 
48 hours after eligibility (Table 5). Dipstick proteinuria, 
when considered as a categorical (rather than continuous) 
variable, yielded higher point estimates for AUC and odds 
ratios in women with 3+ or 4+ dipstick results than in 
women with negative or trace results. For the 24-hour 
urine collection, the AUC was 0.551 for all women who 
had the test and 0.578 for those who had all measures of  
proteinuria including a 24-hour urine collection. However, 
for all tests in the test-speciÀc cohort and the ALL measures 
cohort, the 95% conÀdence intervals for AUC were wide 
and compatible with a weakly discriminative test.
For prediction of  the combined adverse maternal outcome 
within seven days of  eligibility, all point estimates for AUC 
were < 0.70, but for all of  dipstick, spot urine Pr/Cr, and 
24-hour urinary protein, the upper 95% CI crossed 0.70 
(data not shown).
 Table 2. Antenatal measures of proteinuria 
Full cohort
N = 2002 
n (%)
Women with 
ALL measures 
of proteinuria*
N = 434
n (%)
Dipstick 
proteinuria 
cohort
N = 1949 
n (%)
Spot urine 
Pr/Cr cohort
N = 1141 
n (%)
24-hr urinary 
protein cohort
N = 676 
n (%) P†
Dipstick proteinuria (+) 
Negative/trace 485 (242) 109 (251) 485 (249) 358 (314) 146 (216)
0018
1+ 298 (149) 65 (150) 298 (153) 217 (190) 92 (136)
2+ 421 (210) 89 (205) 421 (216) 288 (252) 134 (198)
3 or 4+ 745 (372) 171 (394) 745 (382) 499 (437) 285 (422)
Spot Pr/Cr (mg/mmol) 
spot Pr/Cr ≥ 30 mg/mmol 1101 (550) 332 (765) 1064 (546) 1101 (965) 341 (504)
0465
spot Pr/Cr ≥ 40 mg/mmol 943 (471) 281 (647) 915 (469) 943 (826) 287 (425)
spot Pr/Cr ≥ 50 mg/mmol 851 (425) 260 (600) 826 (424) 851 (746) 266 (393)
24-hr urinary protein excretion (g/d) 
women with 24-hr urinary protein ≥ 03 g/d 535 (267) 333 (767) 523 (268) 340 (298) 535 (791)
0472
women with serum albumin < 20 g/L 15 (28) 5 (15) 14 (27) 5 (15) 15 (28)
women with 24-hr urinary protein ≥ 05 g/d 417 (208) 256 (590) 407 (209) 261 (229) 417 (617)
women with serum albumin < 20 g/L 15 (36) 5 (20) 14 (34) 5 (19) 15 (36)
women with 24-hr urinary protein ≥ 3 g/d 148 (74) 84 (194) 144 (74) 86 (75) 148 (219)
women with serum albumin < 20 g/L 11 (74) 3 (36) 10 (69) 3 (35) 11 (74)
* These women had all three measures of proteinuria assessment
† Continuous variables were compared by ANOVA or Kruskal-Wallis, and categorical variables by chi-square
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For prediction of  the combined adverse maternal outcome 
at any time after eligibility, all point estimates for AUC were 
< 0.70, with most of  the upper 95% conÀdence intervals 
reaching 0.70 (data not shown).
For prediction of  the combined adverse perinatal outcome, 
all point estimates for AUC were < 0.70 (Table 6). When 
dipstick proteinuria was assessed as a categorical variable, 
there were increased odds of  outcome in women with 3+ 
or 4+ proteinuria compared with women with a negative or 
trace dipstick result (OR 2.25; 95% CI 1.74 to 2.92).
None of  the models for a method of  proteinuria assessment 
was sufÀciently robust to proceed with determinations of  
cut-offs that optimized sensitivity and speciÀcity.
Excluding women with non-proteinuric hyperuricemic 
hypertension tended to make all AUC values fall, particularly 
Table 3. Maternal outcomes characteristics, including the PIERS combined adverse maternal outcome within 48 hours 
of eligibility
Full cohort
N = 2002
ALL measures 
of proteinuria
N = 434
Dipstick 
proteinuria 
cohort
N = 1949
Spot urine  
Pr/Cr cohort
N = 1411
24-hour 
urinary 
protein cohort
N = 676 P
Days eligible until delivery, median (IQR) 2 (1–6) 5 (2–11) 2 (1–575) 2 (1–7) 4 (2–10) 0829
Induction, n (%) 1179  (589) 272 (627) 1142  (589) 836 (592) 420 (621) 0322
Ceasarean section, n (%) 1157 (578) 222 (512) 1132 (579) 794 (563) 360 (532) 0023
One or more of PIERS maternal adverse  
outcomes* within 48 hours:
106 (53%) 39 (90%) 101 (52%) 82 (58%) 50 (74%) 0010
Maternal death 0 0 0 0 0
Maternal morbidities:
  Central nervous system
Eclampsia (≥1) 6 1 6 5 1
Glasgow coma score <13 1 0 1 1 0
Stroke or reversible neurological de¿cit 0 0 0 0 0
Cortical blindness or retinal detachment 0 0 0 0 0
Posterior reversible encephalopathy 0 0 0 0 0
Bell’s palsy 0 0 0 0 0
   Cardiorespiratory
Positive inotropic support 0 0 0 0 0
Infusion of a 3rd parenteral antihypertensive 0 0 0 0 0
Myocardial ischemia/infarction 1 0 1 1 0
Pulmonary edema 23 10 22 19 14
Requirement of ≥ 50% FiO2 for >1 hr 12 4 12 10 6
Oxygen saturation < 90% 13 6 12 12 7
Intubation 1 0 1 0 0
   Hematological
Platelet count < 50 × 109/L without transfusion 22 7 21 19 9
Transfusion of any blood product 31 10 31 21 14
   Hepatic                                         
Dysfunction 9 4 9 7 4
Hematoma/rupture 0 0 0 0 0
   Renal                                   
Renal failure 7 4 7 6 5
Dialysis 1 1 1 1 1
Other
Placental abruption 15 7 13 11 7
FiO2: fractional inspired oxygen tension
* These are not mutually exclusive, as some women suffered more than one outcome
594 l JUNE JOGC JUIN 2011
OBSTETRICS
the 24-hour urine value, in predicting adverse maternal 
outcomes. For dipstick proteinuria, the ALL measures 
AUC became 0.521 (95% CI 0.461 to 0.581) for maternal 
outcomes and 0.623 (95% CI 0.560 to 0.686) for perinatal 
outcomes. For Pr/Cr, the respective AUC values became 
0.533 (95% CI 0.469 to 0.596) and 0.564 (95% CI 0.478 
to 0.649), and for 24-hour urine collection, 0.452 (95% CI 
0.369 to 0.535) and 0.625 (95% CI 0.553 to 0.698).
DISCUSSION
In this cohort of  women admitted to hospital with 
preeclampsia, we found that the degree of  proteinuria (as 
assessed by either dipstick testing, spot urine Pr/Cr, or 
24-hour urine collection) was not strongly associated with 
the incidence of  either the combined adverse maternal 
or adverse perinatal outcomes. Dipstick proteinuria 
assessment performed as well as other measures for 
prediction of  adverse outcomes, particularly in the ALL 
measures cohort that consisted of  women who had all 
three types of  proteinuria assessment.
The strengths of  this study include having a cohort of  
women with well-deÀned preeclampsia, investigated in 
a standardized fashion with deÀned laboratory methods 
and standardized, composite outcomes, rather than 
individual, unusual events. Women in the ALL measures 
cohort underwent all three measures of  proteinuria 
assessment, and so results from this group were controlled 
for investigational and management decisions except for 
the proteinuria assessment. Also, proteinuria results were 
examined as a continuous variable, rather than dichotomized 
according to arbitrary or historical thresholds.
Weaknesses of  the study include the multicentre design and 
having a sample size that resulted in wide 95% conÀdence 
intervals for the AUC, particularly for the ALL measures 
cohort. The PIERS project provided guidelines for the 
assessment of  women with preeclampsia. Nevertheless, 
more of  the 2023 women underwent dipstick proteinuria 
assessment (96.3%) than spot Pr/Cr (69.7%) or 24-hour 
urine collection (33.4%). This may reÁect the reluctance of  
clinicians to pursue further testing beyond the triage urinary 
dipstick, perhaps in the face of  certainty about the need for 
delivery at term, when most preeclampsia arises.27 Women 
who underwent 24-hour urine collection did present 
earlier in gestation and more frequently at < 34 weeks, a 
gestational age at which expectant management may be 
considered, and was, in fact, the standard of  care in PIERS 
centres. Lindheimer and Kanter have previously reviewed 
the origins, measurement uncertainty, and interpretation of  
proteinuria in pregnancy.6 Our Àndings are consistent with 
a recent quantitative overview of  relevant observational 
studies in which the level of  proteinuria was not found to 
Table 4. Perinatal demographics and outcomes including the PIERS combined adverse PERINATAL outcome
Full cohort
N = 2002
ALL measures of 
proteinuria
N = 434
Dipstick 
proteinuria cohort
N = 1949
Spot urine  
Pr/Cr cohort
N = 1411
24-hr urinary 
protein cohort
N = 676 P*
GA at delivery, wk,
median (IQR)
369
(341–386)
356
(326–375)
369
(341–386)
369
(344–386)
353
(317–373)
< 0001
Birthweight, g,
median (IQR)
2600
(1785–3254)
2160
(1480–2940)
2603
(1785–3254)
2610
(1838–3245)
2100
(1338–2868)
< 0001
Birth weight < 3rd centile for age,
n babies (%)
164
(82)
48
(111)
161
(83)
120
(85)
68
(101)
0108
Apgar score < 7 at 5 minutes,
n babies (%)
136
(68)
29
(67)
133
(68)
84
(60)
62
(92)
0112
Fetal acidaemia, n (%) 49
(24)
7
(16)
48
(25)
35
(25)
16
(24)
0870
One or more of combined perinatal 
mortality, infant mortality, or 
morbidity†, n
581
(290)
150
(346)
568
(291)
370
(324)
287
(425)
< 0001
Stillbirth 20 4 19 6 12
Neonatal or infant death 26 13 26 17 20
NICU admission > 48 hours 536 133 523 347 255
* Chi-square
† These are not mutually exclusive, as some women suffered more than one outcome
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Table 5. Univariate analysis of the relationship between the proteinuria assessment method performed within  
48 hours of admission and adverse maternal outcome within 48 hours of eligibility
Variable       Population studied N OR (95% CI) P AUC (95% CI)
Dipstick proteinuria (+)   As a categorical variable*
All women with test performed 1949 0545 (0488 to 0601)
1+ 093 (030 to 289) 0895
2+ 080 (028 to 235) 0689
3 or 4+ 139 (060 to 319) 0439
ALL measures cohort 434 0559 (0465 to 0653)
1+ 068 (034 to 137) 0281
2+ 069 (037 to 127) 0230
3 or 4+ 102 (063 to 167) 0925
  As a continuous variable
All women with test performed 1949 104 (089 to 121) 0644 0512 (0454 to 0570)
ALL measures cohort 434 111 (086 to 143) 0419 0539 (0443 to 0634)
Spot Pr/Cr (mg/mol)   All women with test performed 1411 100 (099 to 101) 0731 0484 (0422 to 0546)
ALL measures cohort 434 100 (099 to 101) 0770 0575 (0487 to 0662)
24-hr urinary protein (g/d)   All women with test performed 676 100 (098 to 102) 0987 0551 (0470 to 0631)
ALL measures cohort 434 107 (099 to 116) 0109 0578 (0491 to 0665)
* Compared with negative/trace
Table 6. Univariate analysis of the relationship between the proteinuria assessment method performed within  
48 hours of admission and perinatal outcome
Variable       Population studied N OR (95% CI) P AUC ROC (95% CI)
Dipstick proteinuria (+)   As a categorical variable*
All women with test performed 1949 0605 (0577 to 0623)
1+ 086 (060 to 123) 0413
2+ 122 (090 to 166) 0203
3 or 4+ 225 (174 to 292) < 0001
ALL measures cohort 434 0598 (0542 to 0654)
1+ 072 (036 to 144) 0355
2+ 081 (044 to 151) 0516
3 or 4+ 177 (107 to 293) 0028
  As a continuous variable
All women with test performed 1949 136 (126 to 147) < 0001 0612 (0583 to 0640)
ALL measures cohort 434 123 (106 to  145) 0006 0576 (0518 to 0634)
Spot Pr/Cr (mg/mmol)   Full cohort with test performed 1411 100 (100 to  100) 0001 0570 (0534 to 0605)
ALL measures cohort 434 100 (100 to  100) 0140 0538 (0479 to 0597)
24-hr urinary protein (g/d)   Full cohort with test performed 676 100 (099 to  101) 0845 0643 (0601 to 0686)
ALL measures cohort 434 109 (102 to  116) 0013 0602 (0544 to  0659)
* Compared with negative/trace
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be clinically useful for prediction of  adverse maternal or 
perinatal outcomes.28 However, as the limits of  the 95% 
conÀdence intervals of  the likelihood ratios could not 
rule out some predictive capacity (for perinatal outcomes), 
the authors of  the quantitative overview identiÀed the 
need for future studies. We have been able to address the 
criticism of  heterogeneity in terms of  women enrolled, 
proteinuria testing methods, preeclampsia deÀnition, and 
outcomes (chosen and deÀned) in previous publications.25
In particular, in this publication we have shown that despite 
differences in the deÀnition of  preeclampsia (more often 
hypertension and hyperuricemia for the dipstick cohort) or 
gestational age at presentation (lower for the ALL measures 
and 24-hour urinary protein cohorts), we were unable to 
demonstrate important differences in test performance for 
any of  the three measures of  proteinuria. We were unable 
to address the issue of  statistical power adequately.
Use of  a dipstick to assess proteinuria appeared to perform 
as well as other assessment methods, despite being neither 
sensitive nor speciÀc for abnormal 24-hour protein excretion. 
A Àrst possible explanation for this may be that detecting an 
abnormal amount of  urinary protein excretion (≥ 0.3 g/d) 
with reference to the 95% conÀdence intervals for normal 
pregnancy, as we did, is not necessarily appropriate in 
identifying women (or babies) at increased risk of  problems. 
A second possible explanation is that because dipstick 
proteinuria is a measurement of  both protein excretion and
urine concentration,29 dipstick proteinuria may also reÁect 
plasma volume reduction or subclinical renal dysfunction. A 
third possible explanation is that dipstick proteinuria testing 
is inexpensive and widely available.
In this study, the level of  proteinuria failed to predict 
adverse pregnancy outcomes. Proteinuria reÁects only 
one aspect of  the complex syndrome of  preeclampsia,6
and according to our Àndings, as well as those of  
Thangarantinam et al.,28 proteinuria is clearly insufÀcient as 
a stand-alone predictor of  adverse outcomes. Although it is 
possible that some of  the predictive power of  proteinuria 
may have been attenuated by delivery because of  higher 
levels of  proteinuria,1 a central role of  proteinuria (either 
in the deÀnition of  severe preeclampsia or as a delivery 
indication) should be revisited. In their recent review of  the 
role of  proteinuria assessment in pregnancy, Lindheimer 
and Kanter “recommend that current cut-off  for abnormal 
proteinuria be used to diagnose preeclampsia, but the 
level of  proteinuria should not guide management. Other 
variables, such as status of  blood pressure control, evidence 
of  increasing organ damage in the liver and hematological 
systems, evidence of  falling glomerular Àltration rate, 
and signs of  neurological involvement, are more reliable 
indicators of  severity of  preeclampsia.”6 In view of  the 
Àndings of  the multivariable PIERS modelling study,25 we 
concur with that view.
We found that no method of  proteinuria assessment was 
strongly associated with adverse maternal or perinatal 
outcomes. However, some discriminatory power could not 
be ruled out. Dipstick proteinuria performed as well as other 
methods. These Àndings should encourage reconsideration 
of  the central role of  proteinuria in the classiÀcation of  
the hypertensive disorders of  pregnancy. Suggestions that 
dipstick proteinuria not be used in pregnancy at all should 
also be reconsidered.6 All variables deÀning preeclampsia 
and its severity should be based on an assessment of  the 
risk of  adverse maternal and perinatal outcomes.25
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